LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Suletud

0.32

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.32

Max

0.32

Põhinäitajad
By Trading Economics
Sissetulek	605K -15M
Müük	19M 40M
Kasumimarginaal	-37.72
Töötajad	105
EBITDA	155K -12M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. nov 2025

Turustatistika
By TradingEconomics
Turukapital	-7.2M 75M
Eelmine avamishind	0.32
Eelmine sulgemishind	0.32

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. nov 2025, 21:06 UTC

Suurimad hinnamuutused turgudel

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7. nov 2025, 22:36 UTC

Tulu

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7. nov 2025, 22:22 UTC

Tulu

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q Rev $2.95B >CSU.T

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q Net $210M >CSU.T

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q EPS $9.89 >CSU.T

7. nov 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

7. nov 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

7. nov 2025, 20:59 UTC

Tulu

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7. nov 2025, 20:26 UTC

Market Talk

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7. nov 2025, 20:22 UTC

Tulu

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7. nov 2025, 20:04 UTC

Market Talk

Oil Futures Close Choppy Week With Losses -- Market Talk

7. nov 2025, 19:34 UTC

Market Talk

Gold Posts Small Gain for Week -- Market Talk

7. nov 2025, 19:31 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7. nov 2025, 19:17 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7. nov 2025, 19:09 UTC

Tulu

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7. nov 2025, 19:08 UTC

Tulu

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7. nov 2025, 18:31 UTC

Market Talk

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7. nov 2025, 17:27 UTC

Market Talk

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7. nov 2025, 17:20 UTC

Market Talk

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7. nov 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. nov 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7. nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

7. nov 2025, 17:17 UTC

Omandamised, ülevõtmised, äriostud

Satair Expects to Complete Purchase in Early 2026

7. nov 2025, 17:17 UTC

Omandamised, ülevõtmised, äriostud

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7. nov 2025, 17:15 UTC

Omandamised, ülevõtmised, äriostud

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7. nov 2025, 17:09 UTC

Market Talk

PENN Is Falling Further Behind Competitors -- Market Talk

7. nov 2025, 16:49 UTC

Market Talk

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7. nov 2025, 16:24 UTC

Market Talk

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7. nov 2025, 16:17 UTC

Market Talk

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.